AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Hypophosphatasia

Recent research efforts aimed at curing Hypophosphatasia.

Last updated
Also available in
Français — Hypophosphatasie

Hypophosphatasia

Overview

Hypophosphatasia (HPP) is an inherited condition caused mainly by harmful variants in the ALPL gene, which lowers activity of tissue-nonspecific alkaline phosphatase (TNAP), an enzyme needed for normal mineralization of bones and teeth. Low TNAP allows inorganic pyrophosphate (PPi), a natural brake on mineral formation, to accumulate. HPP ranges from severe prenatal or infantile disease—with poorly mineralized bones, chest-related breathing failure, seizures, and early death without treatment—to childhood, adult, and tooth-predominant forms involving premature tooth loss, fractures or stress fractures, pain, weakness, and disability. GeneReviews: Hypophosphatasia (ncbi.nlm.nih.gov)

The current targeted standard of care is asfotase alfa, a bone-targeted TNAP enzyme-replacement therapy (ERT) given by repeated subcutaneous injection. It has substantially improved survival, skeletal mineralization, and respiratory outcomes in severe pediatric-onset HPP, but it does not repair the underlying ALPL variant and may need to continue lifelong; orthopedic, respiratory, neurologic, dental, pain-management, and rehabilitation care remain important. GeneReviews: Hypophosphatasia (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has been active but remains concentrated in preclinical development rather than human curative trials. The dominant goal is to provide durable TNAP activity—ideally after one treatment—through adeno-associated virus (AAV) gene transfer, gene-modified blood or stromal cells, or engineered B cells; a parallel clinical effort is improving enzyme replacement rather than curing the genetic disease. As of August 8, 2026, the evidence supports genuine disease correction in animal models, but no curative gene, cell, or gene-editing treatment has yet demonstrated clinical benefit in people with HPP. AAV8 TNAP-D10 in mice HSPC gene therapy in mice (pmc.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

AAV gene replacement. The leading preclinical strategy packages a bone-targeted, secreted TNAP construct called TNAP-D10 into AAV vectors. In a 2020 newborn mouse study, a high-dose intramuscular self-complementary AAV8-TNAP-D10 treatment raised circulating alkaline-phosphatase activity, restored major measures of femoral structure and mineralization, and improved predicted bone strength. The dose requirement was important: lower doses prolonged survival but left substantial skeletal abnormalities, showing that survival alone is not an adequate measure of correction. High-dose AAV8-TNAP-D10 study (link.springer.com)

A related AAV8 candidate, ARU-2801, was tested as a one-time muscle-directed treatment in severe HPP-model mice. A single neonatal injection maintained high plasma alkaline-phosphatase activity for up to 18 months and produced mature bone mineralization by computed tomography. ARU-2801 mouse study (sciencedirect.com) Subsequent reported nonhuman-primate work found sustained alkaline-phosphatase activity after intramuscular dosing, with vector DNA mainly detected at the injected muscle and no reported ectopic calcification or tumors in the study period; these findings are encouraging but are not a substitute for human safety and efficacy data. ARU-2801 translational study (jstage.jst.go.jp)

Gene-modified cell therapies. In 2026, investigators reported an autologous-style hematopoietic stem and progenitor cell (HSPC) approach in which cells were modified with a lentiviral vector, RMP100-LVV, to continuously secrete soluble TNAP. In humanized mice and a severe HPP mouse model, the treatment produced durable enzyme activity, improved skeletal disease, and prevented early mortality. This is potentially a one-time treatment model, but it uses integrating lentiviral gene transfer and would require careful assessment of conditioning, insertion-related risks, durability, and manufacturing before clinical use. Lentiviral HSPC therapy study (pubmed.ncbi.nlm.nih.gov)

Fetal gene-cell intervention. Because severe perinatal HPP can damage the skeleton and chest before birth, a 2026 mouse study tested transplantation during gestation of human embryonic-stem-cell-derived mesenchymal stromal cells engineered to express ALPL-D10. Treated HPP-model mice had improved survival, early weight gain, and bone lesions versus untreated controls. This is an especially innovative approach because it attempts to intervene before irreversible prenatal disease develops, but it is at a very early stage and raises substantial fetal-procedure, immunologic, cell-engraftment, and long-term safety questions. In-utero gene-cell therapy study (sciencedirect.com)

Engineered B-cell protein delivery. Be Biopharma’s preclinical candidate BE-102 uses a patient’s engineered B cells as a living source of active TNAP. The company reports that the approach is designed to provide continuous TNAP secretion after a single administration and has shown long-term enzyme activity and reversal of PPi-mediated mineralization inhibition in preclinical models. These are company-reported preclinical data rather than peer-reviewed clinical results, but the platform could be attractive because it is intended to be adjustable and re-dosable. BE-102 program (be.bio)

Clinical Trials and Experimental Approaches

No registered human trial identified in this review is yet testing AAV, HSPC, fetal cell, or engineered-B-cell treatment for HPP. The human interventional pipeline is instead led by efzimfotase alfa (ALXN1850), a next-generation recombinant alkaline-phosphatase replacement designed to improve the practical limitations of existing ERT. In a completed Phase 1 dose-escalation study in 15 adults with HPP sponsored by Alexion Pharmaceuticals, efzimfotase alfa showed acceptable short-term safety and tolerability, dose-related exposure, and pharmacodynamic effects on TNAP substrates; it remains enzyme replacement, not genetic correction. Phase 1 ALXN1850 trial Efzimfotase alfa Phase 1 report (clinicaltrials.gov)

Alexion’s ongoing Phase 3 program includes a randomized placebo-controlled study in 124 treatment-naive adolescents and adults, with primary completion recorded on July 9, 2025 and estimated study completion on March 29, 2028. Pediatric Phase 3 studies include a placebo-controlled trial in treatment-naive children aged 2 to under 12 years and an active-controlled comparison with asfotase alfa in previously treated children; neither registry record reported results as of their latest 2026 updates. Adult Phase 3 ALXN1850 trial Pediatric Phase 3 MULBERRY trial Pediatric Phase 3 CHESTNUT trial (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers use severe TNAP-deficient mouse models, including Alpl/Akp2 knockout mice, to measure survival, seizures, growth, bone mineral density, micro-computed tomography, bone mechanics, tooth and jaw development, PPi levels, and alkaline-phosphatase activity. These models make it possible to compare delivery routes, vector doses, tissue distribution, and unwanted mineralization; importantly, recent AAV studies show that enzyme levels sufficient to keep mice alive may still be insufficient to normalize bone architecture. High-dose AAV8-TNAP-D10 study (link.springer.com)

The principal delivery platforms are muscle-directed AAV8 vectors that turn muscle into a long-term source of circulating bone-targeted TNAP, lentivirally modified HSPCs that engraft and secrete TNAP, engineered B cells that function as controllable protein-producing cells, and mesenchymal stromal cells for prenatal delivery. Across platforms, TNAP activity and its substrates PPi and pyridoxal-5′-phosphate are key pharmacodynamic biomarkers, while vector biodistribution, immune responses, bone imaging, ectopic calcification, and long-term tumor surveillance are central safety measures. ARU-2801 translational study HSPC gene therapy in mice BE-102 program (jstage.jst.go.jp)

Leading Institutions and Funding

The recent preclinical field includes Sanford Burnham Prebys Medical Discovery Institute and collaborators studying AAV-TNAP biology, Nippon Medical School-associated investigators advancing ARU-2801 experiments, and UCLA investigators collaborating with Rampart Bioscience on HSPC-based gene therapy. The 2026 fetal cell-therapy work was supported through Japan’s Agency for Medical Research and Development (AMED) regenerative-medicine and cell-and-gene-therapy acceleration program. AAV8 TNAP-D10 study ARU-2801 translational study HSPC gene therapy in mice In-utero gene-cell therapy study (pmc.ncbi.nlm.nih.gov)

On the clinical and commercial side, Alexion Pharmaceuticals, an AstraZeneca Rare Disease company, is running the advanced efzimfotase alfa trials, while Be Biopharma has selected BE-102 as a preclinical HPP development candidate. These efforts sit alongside patient-focused organizations that support disease awareness, trial participation, and access to specialist care, although the most advanced curative-platform work remains laboratory-based. Adult Phase 3 ALXN1850 trial BE-102 program (clinicaltrials.gov)

Strengths, Limitations, and Challenges

The central strength of HPP cure research is biological clarity: most disease-causing variants reduce a single enzyme activity, and replacing TNAP can correct the downstream PPi excess. AAV, HSPC, B-cell, and fetal-cell approaches have each produced sustained TNAP activity and meaningful disease improvement in animal models, while existing ERT establishes that restoring this enzyme can change clinically important outcomes. AAV8 TNAP-D10 in mice HSPC gene therapy in mice GeneReviews: Hypophosphatasia (pmc.ncbi.nlm.nih.gov)

The major limitations are translation and timing. High AAV doses may be needed for full skeletal correction, yet high systemic AAV exposure can create toxicity concerns; treatment after birth may not reverse developmental damage that arose in the womb; and durable overexpression of a mineralization-promoting enzyme must avoid ectopic calcification. Cell-based approaches introduce further hurdles, including conditioning toxicity for HSPC therapy, insertional risk with lentiviral vectors, immune compatibility, fetal-procedure risk, manufacturing complexity, and equitable access. High-dose AAV8-TNAP-D10 study In-utero gene-cell therapy study HSPC gene therapy in mice (link.springer.com)

Outlook and Future Directions

HPP is not close to having an established human cure, but it is a plausible target for a durable one-time therapy because its core defect is well defined and multiple platforms can supply functional TNAP. The next milestones to watch are publication of the mature ALXN1850 Phase 3 results; formal regulatory or trial-registration progress for AAV, B-cell, or HSPC programs; reproducible large-animal safety data; and evidence that a durable treatment corrects not only biochemical markers and survival, but also bone strength, growth, dental disease, function, and prenatal complications without ectopic mineralization. Adult Phase 3 ALXN1850 trial ARU-2801 translational study BE-102 program (clinicaltrials.gov)

References

Don't see your disease? Request a report